{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362262945375677696.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1097/00007890-199802270-00007"}},{"identifier":{"@type":"URI","@value":"http://journals.lww.com/00007890-199802270-00007"}},{"identifier":{"@type":"PMID","@value":"9500622"}}],"dc:title":[{"@value":"TRANSMISSION OF HEPATITIS B VIRUS FROM HEPATITIS B CORE ANTIBODY-POSITIVE DONORS IN LIVING RELATED LIVER TRANSPLANTS"}],"description":[{"notation":[{"@value":"In order to clarify the risk of hepatitis B virus (HBV) transmission from hepatitis B core antibody-positive (HBcAb(+)) donors and to evolve a new strategy to counter such a risk, we undertook a retrospective (1990-1995) and prospective (1995-1996) analysis of our experience with living related liver transplantation involving HBcAb(+) donors.Between June 15, 1990, and June 30, 1995, HBcAb(+) individuals were not excluded as donor candidates at our institutions. For 171 liver transplants, 16 donors were HBcAb(+). Between July 1, 1995, and June 30, 1996, HBcAb(+) individuals were generally excluded as donor candidates; however, three recipients were given liver grafts from HBcAb(+) donors because other donor candidates presented even higher risks. In the latter period, recipients with transplants from HBcAb(+) donors underwent prophylactic passive immunization with hyperimmune hepatitis B immunoglobulin (HBIG). The serum of 10 HBcAb(+) donors was examined by nested polymerase chain reaction for the presence of HBV-DNA, but it was not detected in any of them. However, the same examination of the liver tissue of five such donors yielded positive results in all cases.In the first 5-year period, out of 16 recipients with HBcAb(+) donors, 15 became hepatitis B surface antigen-positive after transplant. The three recipients with HBcAb(+) donors during the second 1-year period, who were treated by prophylactic passive immunization with HBIG, remained hepatitis B surface antigen-negative and negative for serum HBV-DNA after transplant.HBV exists in the liver of healthy HBcAb(+) individuals, but not in the blood. Therefore, HBV is thought to be transmitted to recipients by liver grafts from the HBcAb(+) donors at a significantly high rate. The prevention of viral activation and clinical disease development by means of passive immunization with HBIG seems promising, although the follow-up period in our study may be too short for any definitive conclusions."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382262945375677569","@type":"Researcher","foaf:name":[{"@value":"Shinji Uemoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262945375677570","@type":"Researcher","foaf:name":[{"@value":"Kohachiro Sugiyama"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262945375677700","@type":"Researcher","foaf:name":[{"@value":"Hiroyuki Marusawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262945375677568","@type":"Researcher","foaf:name":[{"@value":"Yukihiro Inomata"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262945375677697","@type":"Researcher","foaf:name":[{"@value":"Katsuhiro Asonuma"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262945375677699","@type":"Researcher","foaf:name":[{"@value":"Hiroto Egawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262945375677696","@type":"Researcher","foaf:name":[{"@value":"Tetsuya Kiuchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262945375677571","@type":"Researcher","foaf:name":[{"@value":"Yoshishige Miyake"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262945375677572","@type":"Researcher","foaf:name":[{"@value":"Koichi Tanaka"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262945375677698","@type":"Researcher","foaf:name":[{"@value":"Tsutomu Chiba"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00411337"},{"@type":"PISSN","@value":"https://id.crossref.org/issn/00411337"}],"prism:publicationName":[{"@value":"Transplantation"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"1998-02","prism:volume":"65","prism:number":"4","prism:startingPage":"494","prism:endingPage":"499"},"reviewed":"false","url":[{"@id":"http://journals.lww.com/00007890-199802270-00007"}],"createdAt":"2003-12-02","modifiedAt":"2021-04-10","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20virus","dc:title":"Hepatitis B virus"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B","dc:title":"Hepatitis B"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20Core%20Antigens","dc:title":"Hepatitis B Core Antigens"},{"@id":"https://cir.nii.ac.jp/all?q=Polymerase%20Chain%20Reaction","dc:title":"Polymerase Chain Reaction"},{"@id":"https://cir.nii.ac.jp/all?q=Liver%20Transplantation","dc:title":"Liver Transplantation"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20Antigens","dc:title":"Hepatitis B Antigens"},{"@id":"https://cir.nii.ac.jp/all?q=DNA,%20Viral","dc:title":"DNA, Viral"},{"@id":"https://cir.nii.ac.jp/all?q=Living%20Donors","dc:title":"Living Donors"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Family","dc:title":"Family"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20Antibodies","dc:title":"Hepatitis B Antibodies"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004232280833152","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004239680263168","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"<i>De novo</i> activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710501604864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185479120640","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical evaluation of a novel and highly sensitive immunoassay for anti‐hepatitis B core antigen using a fully automated immunochemical analyzer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256755584","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848657466743424","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Successful Active Immunization Using a Hepatitis B Virus Vaccination Protocol for a Recipient With Hepatitis B Core Antibody–Positive Liver Graft"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660743636864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The use of hepatitis B immunoglobulin with or without hepatitis B vaccine to prevent de novo hepatitis B in pediatric recipients of anti‐<scp>HB</scp>c–positive livers"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664422559104","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reactivation of Hepatitis B Virus in Hematopoietic Stem Cell Transplant Recipients in Japan: Efficacy of Nucleos(t)ide Analogues for Prevention and Treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664563123328","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prophylactic managements of hepatitis B viral infection in liver transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204794059264","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of post-transfusion hepatitis by an occult HBV carrier"},{"@value":"Occult HBV感染と考えられる血液製剤による輸血後B型急性肝炎の一例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク Occult HBV カンセン ト カンガエラレル ケツエキ セイザイ ニ ヨル ユケツ ゴ Bガタ キュウセイ カンエン ノ イチレイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204794897408","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Comparative evaluation of PHA (Mycell anti-rHBc) and CLIA (Architect Anti-HBc II) for detecting antibody to hepatitis B core antigen"},{"@language":"ja","@value":"HBc抗体測定系におけるPHA法（マイセルanti-rHBc）とCLIA法（アーキテクト・HBc II）の比較"},{"@language":"ja-Kana","@value":"HBc コウタイ ソクテイケイ ニ オケル PHAホウ(マイセル anti-rHBc)ト CLIAホウ(アーキテクト ・ HBc Ⅱ)ノ ヒカク"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204872779136","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Anti-HBs-Positive Liver Failure Due to Hepatitis B Virus Reactivation Induced by Rituximab"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205078172416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Present state and the future direction of HBV vaccine"},{"@language":"ja","@value":"HBVワクチンの現状と今後の問題点"},{"@language":"ja-Kana","@value":"HBV ワクチン ノ ゲンジョウ ト コンゴ ノ モンダイテン"}]},{"@id":"https://cir.nii.ac.jp/crid/1390005822567511552","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"3) Reactivation of Hepatitis B Virus Caused by Immunosuppressive Therapies and Antineoplastic Chemotherapies"},{"@language":"ja","@value":"3）免疫抑制・化学療法によるB型肝炎の再活性化"},{"@value":"免疫抑制・化学療法によるB型肝炎の再活性化"},{"@language":"ja-Kana","@value":"メンエキ ヨクセイ ・ カガク リョウホウ ニ ヨル Bガタ カンエン ノ サイカッセイカ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679608727552","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Factorial Analysis of Hepatitis B Virus Reactivation-Induced Hepatitis B Using JADER"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679769743360","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B infection derived from a donor and de novo autoimmune hepatitis subsequent to pegylated-interferon treatment for recurrent hepatitis C after living-liver transplantation: A case report"},{"@language":"ja","@value":"生体肝移植後C型肝炎にペグインターフェロン治療を行いドナー由来のHBV再活性化とde novo自己免疫性肝炎を発症した1例"},{"@value":"症例報告 生体肝移植後C型肝炎にペグインターフェロン治療を行いドナー由来のHBV再活性化とde novo自己免疫性肝炎を発症した1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク セイタイ カン イショク ゴ Cガタ カンエン ニ ペグインターフェロン チリョウ オ オコナイ ドナー ユライ ノ HBV サイカッセイカ ト de novo ジコ メンエキセイ カンエン オ ハッショウ シタ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679770766080","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with membranous nephropathy treated with immunosuppression"},{"@value":"膜性腎症の治療経過中に発症したde novo B型肝炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク マクセイジンショウ ノ チリョウ ケイカ チュウ ニ ハッショウ シタ de novo Bガタ カンエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771660672","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Universal vaccination of hepatitis B virus vaccine"},{"@language":"ja","@value":"B型肝炎universal vaccinationへ向けて"},{"@language":"ja-Kana","@value":"Bガタ カンエン universal vaccination エ ムケテ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679772059264","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Comparison of each HBs antigen assay and it's clinical utility"},{"@language":"ja","@value":"HBs抗原の測定法と臨床的意義"},{"@language":"ja-Kana","@value":"HBs コウゲン ノ ソクテイホウ ト リンショウテキ イギ"},{"@value":"Comparison of each HBs antigen assay and it^|^apos;s clinical utility"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681421848320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"10. Current State of Fulminant Hepatitis and Countermeasure for <i>de novo</i> B Hepatitis."},{"@language":"ja","@value":"10．劇症肝炎の現況と<i>de novo</i> B型肝炎対策"},{"@value":"劇症肝炎の現況とde novo B型肝炎対策"},{"@language":"ja-Kana","@value":"ゲキショウ カンエン ノ ゲンキョウ ト de novo Bガタ カンエン タイサク"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681424120192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"6. Viral Hepatitis and Liver Transplantation"},{"@language":"ja","@value":"6．ウイルス性肝炎と肝移植"},{"@value":"ウイルス性肝炎と肝移植"},{"@language":"ja-Kana","@value":"ウイルスセイ カンエン ト カン イショク"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1097/00007890-199802270-00007"},{"@type":"OPENAIRE","@value":"doi_dedup___::d560172ca60c7d89ddfbe58ca7d1fd9d"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.45.1590_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.3851/imp1771_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.1111/hepr.12586_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.2957/kanzo.55.310_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.60_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.2957/kanzo.55.409_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.74_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.2169/naika.100.686_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.2169/naika.102.573_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.1111/hepr.13229_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.2957/kanzo.55.604_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.1016/j.jhep.2014.04.033_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.1007/s00535-016-1168-2_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.1111/petr.13227_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.3390/ijms151121455_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.3748/wjg.v22.i1.165_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.117_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.2222/jsv.62.67_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.1016/j.transproceed.2013.12.005_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.2169/naika.109.1790_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"},{"@type":"CROSSREF","@value":"10.1248/bpb.b16-00765_references_DOI_CEtUJ8oWmbGHN4PuT1N9sc6omq7"}]}